Company Filing History:
Years Active: 2006-2011
Title: Simon Munt: Innovator in Antitumoral Research
Introduction
Simon Munt is a prominent inventor based in Madrid, Spain. He has made significant contributions to the field of antitumoral research, holding a total of 15 patents. His work focuses on developing innovative compounds that aim to combat cancer effectively.
Latest Patents
Among his latest patents are "Antitumoral derivatives of ET-743" and "Antitumoral analogs of ET-743." The first patent provides derivatives of Et-743 or Et-770 or Et-729, characterized by a general formula where the substituent groups have various permitted meanings. The second patent describes antitumor compounds featuring a five-membered fused ring ecteinascidin structure, which notably lacks a 1,4-bridging group found in traditional ecteinascidins. These compounds include a substituent at the C-1 position, selected from either an optionally protected or derivatized aminomethylene group or an optionally protected or derivatized hydroxymethylene group.
Career Highlights
Simon Munt has worked with notable companies in the pharmaceutical industry, including Pharma Mar, S.A. and Pharma Mar, S.A.U. His expertise in antitumoral research has positioned him as a key figure in the development of new cancer therapies.
Collaborations
Throughout his career, Simon has collaborated with esteemed colleagues such as Ignacio Manzanares and Carmen Cuevas. These partnerships have further enhanced his research and innovation in the field.
Conclusion
Simon Munt's contributions to antitumoral research through his patents and collaborations highlight his commitment to advancing cancer treatment. His innovative work continues to inspire progress in the pharmaceutical industry.